{"podcast":{"title":"The Uromigos","slug":"the-uromigos-1214845","podcast_index_feed_id":1214845,"rss_url":"https://anchor.fm/s/13347ea8/podcast/rss","website_url":"https://www.uromigos.org","image_url":"https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_nologo/3122074/3122074-1626815623969-26c22e1d3574c.jpg","author":"The Uromigos","episode_count":479,"summary":"Broadcasting the latest developments in GU cancer Hosted by Brian Rini and Tom Powles Brian Rini MD is an Ingram Professor of Medicine (Hematology/Oncology), Vanderbilt-Ingram Cancer Center Tom Powles is the Director of Barts Cancer Centre, St Bartholomew's Hospital and Professor of Genitourinary Oncology, Queen Mary University of London","last_synced_at":"2026-07-13T22:19:20.611456+00:00","page_url":"https://stenobird.com/podcast/the-uromigos-1214845"},"episode":{"title":"Episode 502: AUA 2026 and FDA bladder cancer meeting","slug":"episode-502-aua-2026-and-fda-bladder-cancer-meeting","published_at":"2026-05-20T15:22:24+00:00","page_url":"https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting","show_page_url":"https://stenobird.com/podcast/the-uromigos-1214845","url":"https://podcasters.spotify.com/pod/show/the-uromigos/episodes/Episode-502-AUA-2026-and-FDA-bladder-cancer-meeting-e3jlaf2","audio_url":"https://anchor.fm/s/13347ea8/podcast/play/120285090/https%3A%2F%2Fd3ctxlq1ktw2nl.cloudfront.net%2Fstaging%2F2026-4-20%2F424548128-44100-2-4ce93ed7c5d5a.m4a","summary":"In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances between CIS and papillary disease. They explore the challenges of drug approvals, the importance of randomized trials, and the emerging data on Deltalimagene, a non-viral gene therapy. The conversation highlights the complexities of treatment options, the need for robust clinical trials, and the future landscape of bladder cancer therapies","meta_description":"In this episode, Brian and Tom engage with Ashish Kamat to discuss the recent FDA meeting focused on bladder cancer treatments, particularly the nuances b…","key_points":[],"chapters":[],"topics":[],"duration_seconds":2116,"processing_state":"not_requested","actions":[{"name":"request_transcript","method":"POST","url":"https://stenobird.com/v1/public/podcasts/the-uromigos-1214845/episodes/episode-502-aua-2026-and-fda-bladder-cancer-meeting/transcription-requests","description":"Idempotently request low-priority transcript generation for this episode."},{"name":"read_markdown","method":"GET","url":"https://stenobird.com/podcast/the-uromigos-1214845/episode-502-aua-2026-and-fda-bladder-cancer-meeting.md","description":"Read the agent-friendly Markdown representation of this episode resource."}]}}